Get Full Access


  • CytoSorbents (NASDAQ: CTSO) CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 40 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury and pancreatitis, as well as in cancer immunotherapy. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant and contract funding in excess of $18 million from DARPA, the U.S. Army, the U.S. Air Force, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM) and others. The Company has numerous products under development based upon this unique blood purification technology, protected by 32 issued U.S. patents and multiple applications pending, including CytoSorb-XL, HemoDefend, ContrastSorb, DrugSorb and others. For more information, please visit the Company's websites: and
  • location

    Headquarters:7 Deer Park Drive Suite K, Monmouth Junction, New Jersey, United States

  • Cytosorbents phone

    Phone Number: +1 732-329-8885

  • Cytosorbents website


  • Cytosorbents employees


  • Cytosorbents revenue

    Revenue:$10 - 50M

  • Cytosorbents legal name

    Legal Name:Cytosorbents

  • Cytosorbents's Social Media

    Cytosorbents linkedin Cytosorbents facebook Cytosorbents twitter
  • done Is this data correct?
  • |  NAICS Code: 339112  |

    Show More
Person level website identification

CEO for Cytosorbents

Phillip Chan

Chief Executive Officer

Person level website visitor identification

Sell more in less time!

Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!

View Employees

Vincent Capponi

President And Chief Operations Officer

Kathleen Bloch

Chief Financial Officer

Fesc Efthymios Deliargyris

Chief Medical Officer

Alan Sobel

Member Board Of Directors And Chairman Of Audit Committee

Al Kraus

Chairman Of The Board

Frequently Asked Questions regarding Cytosorbents

  • Where are Cytosorbents's Headquarters?

    Cytosorbents's Headquarters are in 7 Deer Park Drive Suite K,Monmouth Junction,New Jersey,United States

  • What is Cytosorbents's phone number?

    Cytosorbents's phone number is +1 732-329-8885

  • What is Cytosorbents's official website?

    Cytosorbents's official website is

  • What is Cytosorbents's Revenue?

    Cytosorbents's revenue is $10 - 50M

  • What is Cytosorbents's NAICS code?

    Cytosorbents's NAICS code is 339112

  • How many employees are working in Cytosorbents

    Cytosorbents has 124 employees

  • What is Cytosorbents's Industry?

    Cytosorbents is in the industry of Medical Devices

  • Who is Cytosorbents's CEO?

    Cytosorbents's CEO is Phillip Chan

Company Directory